King & Spalding partner J. Philip Ludvigson sat down with two Navlin Daily reporters to discuss the dynamics between the United States and China when it comes to cross-border biotech dealmaking, investments and acquisitions regulations.  

He notes that policymakers and businesses in both countries must navigate issues like geopolitical tensions and differing pharmaceutical laws when negotiating regulations.  

“But beyond that, I think there’s also a broader kind of national security concern of being reliant on something from abroad and not having the ability to replicate that yourself,” Mr. Ludvigson said.  

Read the full article here: 

Finalization of U.S. Controls on China Dealmaking is ‘Almost Certain’: Legal Expert